Then, as the BCL2 anti-apoptosis factor is frequently overexpressed in NHL and specifically in DLBCL (30), we evaluated its expression profile in several cancer types (from the TCGA database) and we confirmed its overexpression specifically in DLBCL and acute myeloid leukemia (AML) (Supplementary Figure S2B). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.